Mostafa Elmokhtar Belghasem

Instructor, Pathology & Laboratory Medicine

(617) 414-7060
670 Albany St Biosquare III

Publications

  • Published on 11/22/2017

    Shashar M, Belghasem ME, Matsuura S, Walker J, Richards S, Alousi F, Rijal K, Kolachalama VB, Balcells M, Odagi M, Nagasawa K, Henderson JM, Gautam A, Rushmore R, Francis J, Kirchhofer D, Kolandaivelu K, Sherr DH, Edelman ER, Ravid K, Chitalia VC. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci Transl Med. 2017 Nov 22; 9(417). PMID: 29167396.

    Read at: PubMed
  • Published on 11/17/2016

    Fan X, Yang H, Kumar S, Tumelty KE, Pisarek-Horowitz A, Rasouly HM, Sharma R, Chan S, Tyminski E, Shamashkin M, Belghasem M, Henderson JM, Coyle AJ, Salant DJ, Berasi SP, Lu W. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight. 2016 Nov 17; 1(19):e86934. PMID: 27882344.

    Read at: PubMed
  • Published on 5/27/2015

    Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol. 2016 Jan; 27(1):189-201. PMID: 26019318.

    Read at: PubMed
  • Published on 3/19/2014

    Sowmya Shivanna, Moshe Shashar, Elena Metrikova, Mostafa Belghasem, Vipul Chitalia. Enhanced Proliferative but not the Pro-Thrombotic Potential of Vascular Smooth Muscle Cells with Telomerase is Compromised Concurrent with P53 Induction. 2014; 2(J Cardio V):1-8.

    Read at: Custom

View all profiles